Journal of Ocular Pharmacology and Therapeutics最新文献

Rose Bengal-Assisted Photodynamic Antimicrobial Therapy for Keratitis. 玫瑰bengal辅助光动力抗菌治疗角膜炎。

IF 1.9 4区医学

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2025-05-29 DOI: 10.1089/jop.2025.0010

Aravind Roy, Uday B Kompella

引用次数: 0

Topical Cyclosporine and Steroid Treatments: A Comparative Approach to Membranous Punctal Stenosis. 局部环孢素和类固醇治疗：膜性点状狭窄的比较方法。

IF 1.9 4区医学

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2025-05-15 DOI: 10.1089/jop.2025.0036

Saidali Kholzoda, Gamze Özkan, Volkan Dericioğlu, Semra Akkaya Turhan

{"title":"Topical Cyclosporine and Steroid Treatments: A Comparative Approach to Membranous Punctal Stenosis.","authors":"Saidali Kholzoda, Gamze Özkan, Volkan Dericioğlu, Semra Akkaya Turhan","doi":"10.1089/jop.2025.0036","DOIUrl":"https://doi.org/10.1089/jop.2025.0036","url":null,"abstract":"Purpose: To compare the efficacy of topical cyclosporine A (CsA) and steroid treatment in the membranous punctal stenosis (PS). Methods: Forty-eight patients with membranous PS were divided into 2 groups: 23 eyes of 13 patients received topical CsA for 6 months as Group CsA and 25 eyes of 14 patients received topical steroid for 3 months as Group S. Examinations were performed before and at 1, 3, 6, and 9 months after treatment. Clinical evaluations involved the Munk score and the fluorescein dye disappearance test (FDDT). Anterior segment optical coherence tomography was employed to measure tear meniscus height (TMH), tear meniscus area (TMA), and outer punctum diameter (OPD). TMH was also examined with biomicroscopy (TMH-Bio). A questionnaire was administered to assess patient satisfaction. Results: Munk score and FDDT grade decreased in both groups at all follow-ups compared with the pre-treatment. TMH-Bio was lower in the Group CsA at all follow-up visits compared with baseline (P < 0.001). TMA and TMH decreased in the Group CsA compared with pre-treatment at 6 months after treatment, whereas there were no changes in the Group S. OPD was larger at 9 months in both groups compared with baseline. The patients' satisfaction was higher in Group CsA at the 6th month compared with Group S. Conclusions: CsA has demonstrated the potential to be a more effective treatment option for the management of PS, with additional advantages compared with topical steroid, such as higher patient satisfaction and favorable functional outcomes.","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Steroid-Induced Ocular Hypertension in Children: A Review on Risk Factors. 儿童类固醇性高眼压：危险因素综述。

IF 1.9 4区医学

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2025-05-13 DOI: 10.1089/jop.2025.0024

Sebastian Lacau, Alejandro Marin, Elena Bitrian

{"title":"Steroid-Induced Ocular Hypertension in Children: A Review on Risk Factors.","authors":"Sebastian Lacau, Alejandro Marin, Elena Bitrian","doi":"10.1089/jop.2025.0024","DOIUrl":"https://doi.org/10.1089/jop.2025.0024","url":null,"abstract":"Purpose: Steroid-induced ocular hypertension is poorly understood in children, despite its frequent occurrence. Significant knowledge voids exist in steroid responsiveness, especially in the pediatric population. Therefore, highlighting the most critical risk factors in pediatric patients can help ophthalmologists identify who is at increased risk of developing a high steroid response.Methods: A manual search was conducted in PubMed and Google Scholar in search of relevant articles on the steroid-induced glaucoma subtopic.Results: Key risk factors for high steroid response include glaucoma family history, previous glaucoma diagnosis, young age, steroid type, administration route, and diseases such as vernal keratoconjunctivitis (VKC) and uveitis. Clinically, it presents similarly to primary glaucoma, except for steroid usage history. Steroid cessation or reduction can normalize intraocular pressure (IOP) levels; however, in some cases, pressure-lowering drugs are necessary for treatment.Conclusion: Topical ocular steroids are frequently used by pediatricians and ophthalmologists alike. Understanding the importance of risk factors allows for a timely diagnosis of steroid response and adequate treatment before glaucomatous vision loss can occur.","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144026934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-World Safety Profile of Cenegermin Per FDA Adverse Event Reporting System. 根据FDA不良事件报告系统，genegermin的实际安全性概况。

IF 1.9 4区医学

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2025-05-07 DOI: 10.1089/jop.2025.0023

Hassaam S Choudhry, Mingzhuo Pei, David Mothy, Julie Scarfuto, Shahzad I Mian

{"title":"Real-World Safety Profile of Cenegermin Per FDA Adverse Event Reporting System.","authors":"Hassaam S Choudhry, Mingzhuo Pei, David Mothy, Julie Scarfuto, Shahzad I Mian","doi":"10.1089/jop.2025.0023","DOIUrl":"https://doi.org/10.1089/jop.2025.0023","url":null,"abstract":"Purpose: To characterize the safety profile of cenegermin through an analysis of postmarket adverse events (AEs). Methods: The U.S. Food and Drug Administration adverse event reporting system was queried for AEs associated with cenegermin use between 2019 and 2023. Demographic information was collected. Reporting odds ratio (ROR) and proportional reporting ratio (PRR) were used to determine adverse reactions that were significantly more likely to be caused by cenegermin use compared with other ophthalmical topicals. Results: Most AEs occurred in females (65.16%). The most common AEs were eye pain (46.94%), irritation (14.46%), and ocular hyperemia (9.8%). Of 34 eye disorders that were found to be associated with cenegermin use, the ones with the highest odds ratios were periorbital pain [ROR: 25.34, confidence interval (CI): 20.70-31.01, PRR: 16.45], eyelid pain (ROR: 22.96, CI: 19.39-27.19, PRR: 15.50), and eye pain (ROR: 20.02, CI: 18.77-21.35, PRR: 16.08). Patients taking cenegermin were significantly more likely to develop eye disorders (ROR: 2.21, CI: 2.12-2.31, PRR: 1.46), but were not more likely to develop disorders of other system organ classes. In terms of patient outcomes, patients taking cenegermin were at higher risk for hospitalization (ROR: 16.39, CI: 12.84-20.94, PRR: 12.17) and surgery (ROR: 9.57, CI: 6.14-14.93, PRR: 8.01). Conclusion: Postmarket surveillance of cenegermin demonstrates that eye pain and irritation are the most common AEs. Involvement of other organ systems is highly unlikely. Patients using topical cengermin should be counseled accordingly.","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144009912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endoplasmic Reticulum Stress as a Regulator of High Glucose-Induced Epithelial-Mesenchymal Transition in Human Lens Epithelial Cells. 内质网应激在高糖诱导的人晶状体上皮细胞上皮-间质转化中的调节作用。

IF 1.9 4区医学

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2025-05-05 DOI: 10.1089/jop.2024.0210

Hui Li, Jing Yang

{"title":"Endoplasmic Reticulum Stress as a Regulator of High Glucose-Induced Epithelial-Mesenchymal Transition in Human Lens Epithelial Cells.","authors":"Hui Li, Jing Yang","doi":"10.1089/jop.2024.0210","DOIUrl":"https://doi.org/10.1089/jop.2024.0210","url":null,"abstract":"Purpose: Diabetic patients have been proven to have higher incidence of subcapsular cataract, and the subcapsular cataract formation has a closed link with epithelial-to-mesenchymal transition (EMT). EMT in numerous tissues can be regulated by the endoplasmic reticulum stress response (ER stress). In this study, we aim to explore the role of ER stress high glucose (HG)-induced EMT of human lens epithelial cells (HLECs). Methods: The human lens epithelial cell line SRA01/04 was treated under HG conditions, and 4-phenylbutyrate (PBA) or tauroursodeoxycholic acid (TUDCA) was used for 24 h to restore endoplasmic reticulum (ER) homeostasis under HG condition. The long axis and the aspect ratio of the cells were analyzed with ImageJ software to evaluate the morphology of the cells. Western blot analysis and immunofluorescence staining were applied to measure ER stress makers: glucose-regulated protein 78 (GRP78), phosphorylation of eukaryotic initiation factor-2α (P-eIf2α), activating transcription factor 6 (ATF6), phospho-inositol-requiring enzyme1 (P-IRE1α), and the EMT makers: fibronectin, vimentin, alpha-smooth muscle actin (α-SMA), and N-cadherin. Additionally, wound-healing assays were performed to evaluate the cell migration ability. Results: Under HG, the morphology of HLECs became elongated, accompanied by a significantly increased cellular aspect ratio. Both the expression of ER stress markers (GRP78, P-eIF2α, ATF6, and P-IRE1α) and the EMT markers (fibronectin, vimentin, αSMA, and N-cadherin) increased. Conversely, the expression of E-cadherin, a marker of epithelial cells, decreased, and wound-healing assays indicated enhanced cell migration ability. All of these alterations were inhibited by PBA or TUDCA treatment. Conclusions: ER stress regulates HG-induced EMT in lens epithelial cells.","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corneal Complications: Drug-Induced Deposits and Food and Drug Administration Adverse Event Reporting System Data Insights-A Retrospective Study. 角膜并发症：药物引起的沉积物和食品药品监督管理局不良事件报告系统数据见解-一项回顾性研究。

IF 1.9 4区医学

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2025-05-05 DOI: 10.1089/jop.2024.0178

Owais M Aftab, Hamza Khan, Bushra Aftab, Waqas Haque, Yassine J Daoud

{"title":"Corneal Complications: Drug-Induced Deposits and Food and Drug Administration Adverse Event Reporting System Data Insights-A Retrospective Study.","authors":"Owais M Aftab, Hamza Khan, Bushra Aftab, Waqas Haque, Yassine J Daoud","doi":"10.1089/jop.2024.0178","DOIUrl":"https://doi.org/10.1089/jop.2024.0178","url":null,"abstract":"Purpose: The aim of this study was to identify and quantify the occurrence of corneal deposits caused by medications, utilizing data from the Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: We conducted a retrospective analysis of the national FAERS database, focusing on instances of drug-induced corneal deposits reported between 2004 and the third quarter of 2023. Our methodology included applying the proportional reporting ratio, reporting odds ratio, empirical Bayes geometric mean, and information component in our disproportionality analysis. A signal was considered present if all four of these disproportionality metrics showed positive results. Results: Over the span of 20 years, our research identified 383 adverse event reports linked to corneal deposits associated with 349 different medications. The most common age-group of these reports involved patients over 65 years of age (32.4%), with equal distribution between male (40.0%) and female (42.8%) patients. Thirty-one medications showed a positive signal. Notably, drugs such as amiodarone (68 reports), prednisolone (60 reports), and timolol (54 reports) were most frequently mentioned. Cyclopentolate and chloramphenicol demonstrated robust statistical relevance in association with corneal deposits. Conclusions: Positive signals for drug-induced corneal deposits included both well-known medications such as amiodarone and lesser-studied medications such as prednisolone and timolol. Clinician awareness of these findings alongside further investigation is needed.","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corticosteroid as Treatment in Infective Conjunctivitis: A Systematic Literature Review and Meta-Analysis. 皮质类固醇治疗感染性结膜炎：系统文献综述和荟萃分析。

IF 1.9 4区医学

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2025-05-01 Epub Date: 2025-03-10 DOI: 10.1089/jop.2024.0110

Lily Raudah Putri, Lukman Edwar

{"title":"Corticosteroid as Treatment in Infective Conjunctivitis: A Systematic Literature Review and Meta-Analysis.","authors":"Lily Raudah Putri, Lukman Edwar","doi":"10.1089/jop.2024.0110","DOIUrl":"10.1089/jop.2024.0110","url":null,"abstract":"Corticosteroid use as an anti-inflammatory agent in infective conjunctivitis has been met with concerns about prolonged infection. This systematic review aims to evaluate the safety and efficacy of corticosteroids as a treatment for infective conjunctivitis. A comprehensive search was conducted on PubMed, Cochrane, Scopus, ScienceDirect, Embase, and ProQuest for clinical trials of topical corticosteroids with or without combination with other medications in bacterial or viral conjunctivitis up to November 2023. The studies were screened, and data on safety and efficacy were extracted. The quality of studies was assessed using the Jadad Scale. Meta-analysis was performed using the random-effects model, with heterogeneity assessed with the I2 statistic. We found ten clinical trials that met the inclusion criteria. Overall meta-analysis revealed significant clinical resolution in dexamethasone-containing therapy compared to non-corticosteroid treatment (OR 1.51; 95% CI 1.19-1.92), with several studies reporting significantly reduced clinical symptoms severity. Two of the six studies assessing viral and bacterial eradication reported significantly improved viral clearance rates. Meta-analysis indicated no difference in ocular adverse effects compared to nonsteroid therapy (OR 1.33; 95% CI 0.82-2.16). In conclusion, corticosteroid use in infective conjunctivitis is relatively safe and may help improve clinical resolution and reduce symptom severity, especially when combined with antibiotics and antiseptics.","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"187-198"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

DOCK1/ELMO1/Rac1 Signaling is Essential for Vitreous-Induced Migration and Contraction of ARPE19 Cells. DOCK1/ELMO1/Rac1信号是玻璃体诱导ARPE19细胞迁移和收缩的必要条件。

IF 1.9 4区医学

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2025-05-01 Epub Date: 2025-02-06 DOI: 10.1089/jop.2024.0173

Duo Li, Yikeng Huang, Hetian Lei, Xionggao Huang

{"title":"DOCK1/ELMO1/Rac1 Signaling is Essential for Vitreous-Induced Migration and Contraction of ARPE19 Cells.","authors":"Duo Li, Yikeng Huang, Hetian Lei, Xionggao Huang","doi":"10.1089/jop.2024.0173","DOIUrl":"10.1089/jop.2024.0173","url":null,"abstract":"Purpose: To test the effects of dedicator of cytokinesis protein 1 (DOCK1) with its binding partner engulfment and cell motility protein 1 (ELMO1)-Rac1 axis on the vitreous-induced biological functions of retinal pigment epithelial (RPE) cells. Methods: Rac1 activity in RPE cells after vitreous stimulation was detected via a pull-down assay. The related protein expression levels were examined via western blot analysis. DOCK1 and ELMO1 knockdown cells were generated via CRISPR-Cas9 technology. Cytoskeletal reorganization was detected by immunofluorescent localization of F-actin. Cell proliferation, migration, invasion, and contraction ability were measured via the CCK8 assay, wound healing assay, transwell invasion assay, and collagen contraction assay. Results: Rac1 activity was significantly elevated in ARPE-19 cells stimulated with vitreous fluid for 30 min to 3 h. Depletion of either DOCK1 or ELMO1 with CRISPR/Cas9 attenuated vitreous-stimulated Rac1 activity, thus reversing the vitreous-induced cytoskeletal rearrangements. The functional cell biology results revealed that deficiencies of DOCK1 and ELMO1 significantly impeded the migration, invasion, and contraction abilities of vitreous-stimulated human RPE cells. Conclusion: This study demonstrated that the DOCK1/ELMO1-Rac1 axis plays an essential role in the pathogenesis of proliferative vitreoretinopathy (PVR), thus suggesting that interruption of this axis has potential for PVR therapy.","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"217-225"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Results of the Use of a Combined Solution of 0.5% Carboxymethylcellulose, 0.9% Glycerin, and 3% Trehalose for the Treatment of Dry Eye Disease. 使用0.5%羧甲基纤维素、0.9%甘油和3%海藻糖联合溶液治疗干眼症的临床结果

IF 1.9 4区医学

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2025-05-01 Epub Date: 2025-02-27 DOI: 10.1089/jop.2024.0115

Pedro-Ivan Navarro-Naranjo, Alberto Chacon-Aponte, Gerardo Artunduaga-Rodriguez

{"title":"Clinical Results of the Use of a Combined Solution of 0.5% Carboxymethylcellulose, 0.9% Glycerin, and 3% Trehalose for the Treatment of Dry Eye Disease.","authors":"Pedro-Ivan Navarro-Naranjo, Alberto Chacon-Aponte, Gerardo Artunduaga-Rodriguez","doi":"10.1089/jop.2024.0115","DOIUrl":"10.1089/jop.2024.0115","url":null,"abstract":"Objective: To describe the clinical effects of a novel, combined ocular lubricant for treating patients with dry eye disease. Methods: A noncomparative, retrospective cohort of 67 eyes (67 patients) with a confirmed diagnosis of dry eye disease using the ocular surface disease index (>12), tear osmolarity, and ocular surface parameters (noninvasive break-up time, meniscus height, and meibography) evaluated using the Cornea550 were included. All patients were treated with a combination of 0.5% carboxymethylcellulose, glycerin 0.9%, and trehalose 3% with a dosing regimen of one drop four times a day for 1 month with a final evaluation of the same parameters. Results: We included 67 eyes (80.6% females) with a mean age of 48.3 ± 16.2 years (standard deviation [SD]). In total, 37% of the subjects had comorbidities such as hypothyroidism (9%), ocular rosacea (4%), Sjogren's syndrome (4%), and arterial hypertension (4%). Of these, 34% were taking systemic medications and 56.7% had previous ocular surgery. The mean ocular surface disease index score before treatment was 57.6 ± 17.2 (SD) and 22.2 ± 12.9 points (SD) after treatment (P < 0.05). Other parameters such as noninvasive break-up time, meniscus height, and meibography improved without a statistically significant difference. Conclusion: Cristal Tears Plus is a novel, combined, and multipurpose treatment for dry eye disease.","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"210-216"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lotilaner for Demodex Blepharitis: The Journey from Veterinary Use to Human Medicine. 用于眼睑蠕形螨炎的洛替兰：从兽医用药到人类用药的历程。

IF 1.9 4区医学

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2025-05-01 Epub Date: 2025-03-13 DOI: 10.1089/jop.2024.0145

Akanksha Sharma, Pankaj Kumar Sharma, Uday B Kompella

{"title":"Lotilaner for Demodex Blepharitis: The Journey from Veterinary Use to Human Medicine.","authors":"Akanksha Sharma, Pankaj Kumar Sharma, Uday B Kompella","doi":"10.1089/jop.2024.0145","DOIUrl":"10.1089/jop.2024.0145","url":null,"abstract":"In 2023, Xdemvy® (0.25% lotilaner ophthalmic solution) was approved by the U.S. FDA for treating Demodex blepharitis in humans. This article reviews lotilaner's history, physicochemical properties, pharmacokinetics, pharmacology, clinical outcomes, and other indications for which it is being evaluated clinically. Furthermore, the article discusses Demodex blepharitis, alternative treatments used in the clinic to ameliorate its symptoms, and other drugs in development. Prior to its approval in humans, lotilaner found extensive application in treating parasitic infections in cats and dogs. Lotilaner was previously approved in 2017 as an oral veterinary medicine (Credelio®) for canines to treat demodicosis, other mite infections, and tick infections. Lotilaner belongs to the isoxazoline class of drugs and is a potent arthropod-selective gamma-aminobutyric acid-gated chloride ion channel inhibitor. Like several other drugs in the isoxazoline class, lotilaner has a long plasma half-life and high plasma protein binding of about 99.9%. When used as indicated, lotilaner treats infested Demodex blepharitis in 42 days, with its antiparasitic action starting within 24 h. Furthermore, lotilaner is also being evaluated for its efficacy in other conditions such as Lyme disease and dry eye disease. Other products evaluated for treating Demodex blepharitis include ivermectin eye ointment, ivermectin-metronidazole gel, permethrin cream, terpinen-4-ol wipes, and hypochlorous acid spray. Along with these, azithromycin eye drop, azithromycin/loteprednol eye drop, and other treatments are being evaluated for treating blepharitis. Other drugs from the isoxazoline drug class including afoxolaner, sarolaner, and fluralaner, could also be potentially explored for human use.","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":"173-186"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0